Expected earnings - SAB Biotherapeutics Inc.
Source: US Earnings Reports
SAB Biotherapeutics Inc. (SABS) is expected to report $-0.82 for Q2 2025
SAB Biotherapeutics Inc.
NASDAQ: SABS
SABS Trading
2.87% G/L:
$4.665 Last:
553,421 Volume:
$4.87 Open:
SABS Latest News
March 10, 2026 07:31:00 am
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
January 07, 2026 08:00:00 am
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
SABS Stock Data
$198,996,637
35,676,574
26.21%
14
N/A
Biotechnology & Life Sciences
Healthcare
US
Miami Beach
